Needham & Company LLC Cuts Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $510.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price lowered by Needham & Company LLC from $529.00 to $510.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently weighed in on ALNY. Morgan Stanley cut their price target on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a research note on Friday, January 30th. Piper Sandler reissued an “overweight” rating and set a $489.00 target price (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Wall Street Zen upgraded Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 10th. Barclays started coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 price target for the company. Finally, Oppenheimer assumed coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price objective on the stock. Twenty-two analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $477.38.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $314.40 on Thursday. Alnylam Pharmaceuticals has a 1 year low of $205.87 and a 1 year high of $495.55. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. The firm has a market capitalization of $41.54 billion, a PE ratio of 183.86 and a beta of 0.35. The business has a 50 day simple moving average of $374.98 and a 200-day simple moving average of $424.68.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.61). The company had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 119.85%. The firm’s quarterly revenue was up 84.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.65) earnings per share. Equities research analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 9,577 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $362.86, for a total value of $3,475,110.22. Following the transaction, the chief executive officer directly owned 78,411 shares in the company, valued at approximately $28,452,215.46. This trade represents a 10.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Tolga Tanguler sold 1,510 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $547,933.70. Following the completion of the transaction, the executive vice president directly owned 29,728 shares in the company, valued at approximately $10,787,399.36. The trade was a 4.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 31,305 shares of company stock valued at $12,459,785. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ALNY. Thematics Asset Management bought a new stake in Alnylam Pharmaceuticals during the second quarter valued at $1,995,000. Mediolanum International Funds Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $11,389,000. Teacher Retirement System of Texas raised its stake in Alnylam Pharmaceuticals by 3.2% during the second quarter. Teacher Retirement System of Texas now owns 36,408 shares of the biopharmaceutical company’s stock worth $11,872,000 after acquiring an additional 1,123 shares during the period. Rakuten Investment Management Inc. bought a new position in Alnylam Pharmaceuticals in the third quarter worth about $14,205,000. Finally, Generali Asset Management SPA SGR boosted its stake in Alnylam Pharmaceuticals by 6,368.0% in the third quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock valued at $1,475,000 after acquiring an additional 3,184 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Amvuttra is powering large revenue gains and Alnylam reported full-year product revenues near $3B with strong year‑over‑year growth; the company also reported profitability for the first time — a clear fundamental positive for long‑term earnings potential. Business Wire: Alnylam Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Catalyst from analyst support — some firms (e.g., TD Cowen) are maintaining Buy ratings and framing Amvuttra as the catalyst for a longer‑term profitability inflection. TipRanks: Amvuttra-Driven Profitability Inflection Supports Buy Rating
• Neutral Sentiment: FY‑2026 revenue guidance was updated to roughly $5.3–$5.8B (slightly wide band vs. consensus), leaving mixed readthroughs for near‑term estimates and valuation models. Business Wire: FY‑2026 Guidance
• Neutral Sentiment: Analysts have trimmed price targets (e.g., Chardan, Needham) but many kept Buy ratings — this tempers upside expectations while still signaling continued institutional conviction. Benzinga: Analyst Price Target Changes
• Negative Sentiment: Market reaction to the Q4 release was mixed: some outlets flagged EPS and revenue misses vs. specific consensus numbers while others reported an EPS beat — the inconsistent takeaways have created volatility and investor uncertainty. Zacks: Q4 Earnings Beat, Sales Miss MarketBeat: Q4 Snapshot
• Negative Sentiment: Management signaled higher long‑term R&D/spend to fund pipeline ambitions and flagged execution/scaling risks for global Amvuttra rollout — comments that prompted some investors to downgrade longer‑term profit expectations. Seeking Alpha: Investors Revise Future Profit Expectations TipRanks: Execution Risks Loom
• Neutral Sentiment: Reported short‑interest figures in the feeds are effectively zero/placeholder and not informative for current positioning — ignore as a market signal until clearer data is posted.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.